Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services
Portfolio Pulse from Benzinga Newsdesk
Quanterix is inviting laboratories to explore partnership opportunities for Alzheimer's disease testing, focusing on Tau protein measurement using its patented technique under U.S. Patent No. 11,275,092.
March 21, 2024 | 9:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quanterix is seeking partnerships with labs for Alzheimer's disease testing services, leveraging its patented Tau protein measurement technology.
By inviting laboratories to partner for Alzheimer's disease testing, Quanterix is potentially expanding its market reach and application of its patented technology. This move could lead to increased demand for its services and technology, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90